CervoMed (CRVO) Non-Current Deferred Tax Liability (2013 - 2021)
CervoMed (CRVO) posted Non-Current Deferred Tax Liability of $443893.0 for Q2 2021, little changed sequentially from $443893.0 in Q1 2021, and down 64.48% YoY from $1.2 million in Q2 2020.
CervoMed (CRVO) Non-Current Deferred Tax Liability (2013 - 2021) Analysis & Trends
CervoMed has reported Non-Current Deferred Tax Liability for 9 years, with the latest figure at $443893.0 in Q2 2021.
- Quarterly Non-Current Deferred Tax Liability fell 64.48% year-over-year to $443893.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $443893.0 (down 64.48% YoY) and the FY2020 annual result came in at $443893.0, down 79.05% from the prior year.
- Non-Current Deferred Tax Liability steadied at $443893.0 in Q2 2021 per CRVO's latest filing, from $443893.0 in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $3.3 million in Q1 2017 and troughed at $443893.0 in Q3 2020.
- A 5-year average of $1.7 million and a median of $1.7 million in 2018 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2019 and 2020: Non-Current Deferred Tax Liability grew 18.63% in 2019, then plunged 79.05% in 2020.
- Over 5 years, Non-Current Deferred Tax Liability stood at $2.2 million in 2017, then retreated by 19.67% to $1.8 million in 2018, then rose by 18.63% to $2.1 million in 2019, then slumped by 79.05% to $443893.0 in 2020, then changed by 0.0% to $443893.0 in 2021.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $443893.0, $443893.0, and $443893.0 for Q2 2021, Q1 2021, and Q4 2020 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CervoMed | 26.64 Mn | 26.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 443,893.00 |
| Jun 30, 2021 | 443,893.00 |
| Mar 31, 2021 | 443,893.00 |
| Mar 31, 2021 | 443,893.00 |
| Dec 31, 2020 | 443,893.00 |
| Dec 31, 2020 | 443,893.00 |
| Sep 30, 2020 | 443,893.00 |
| Sep 30, 2020 | 443,893.00 |
| Jun 30, 2020 | 1.25 Mn |
| Jun 30, 2020 | 1.25 Mn |
| Mar 31, 2020 | 1.76 Mn |
| Mar 31, 2020 | 1.76 Mn |
| Dec 31, 2019 | 2.12 Mn |
| Dec 31, 2019 | 2.12 Mn |
| Sep 30, 2019 | 1.30 Mn |
| Sep 30, 2019 | 1.30 Mn |
| Jun 30, 2019 | 1.53 Mn |
| Jun 30, 2019 | 1.53 Mn |
| Mar 31, 2019 | 1.64 Mn |
| Mar 31, 2019 | 1.64 Mn |